chloroquine - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 1.37 [0.73, 2.56]> 10%1 study (1/-)83.8 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.37 [0.73, 2.56]> 10%1 study (1/-)83.8 %some concernnot evaluable moderateimportant-
PCR-negative conversion (14-day) 1.09 [0.95, 1.26]> 10%1 study (1/-)88.2 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 1.20 [0.60, 2.40]> 10%1 study (1/-)69.7 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.33 [0.94, 1.88]> 10%1 study (1/-)94.7 %some concernnot evaluable moderateimportant-

-- safety endpoints 00

adverse events 1.80 [0.14, 23.37]< 10%1 study (1/-)32.8 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 95,94,90,91 95